Palbociclib in Combination With Chemotherapy in Pediatric Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (RELPALL2)

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 9, 2021

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Acute Lymphoblastic Leukemia, PediatricRelapsed Acute Lymphoblastic LeukemiaRefractory Acute Lymphoblastic Leukemia

Interventions

DRUG

Palbociclib

Oral

DRUG

Dexamethasone

8 mg/m2/day divided BID, PO, NG, or IV

DRUG

Bortezomib

1.3 mg/m2/dose, IV (preferred) or SC

DRUG

Doxorubicin

25 mg/m2/dose IV

Trial Locations (1)

RECRUITING

Lucile Packard Children's Hospital Stanford, Stanford

All Listed Sponsors

lead

Tanja Andrea Gruber

OTHER